Enavogliflozin vs Ertugliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Enavogliflozin · Envlo
Marketed by Daewoong Pharmaceutical and partners
NCT04634500 · Phase 3 · completed
This Phase 3 trial randomly assigned 200 people with type 2 diabetes to enavogliflozin or to dapagliflozin, with participants and investigators unaware of assignment. It was designed to show enavogliflozin was not worse than dapagliflozin at lowering HbA1c over 24 weeks, within a margin of 0.35 percentage points. It met that test: HbA1c fell by 0.80 percentage points on enavogliflozin against 0.75 on dapagliflozin, a difference of 0.04 points (95% CI -0.21 to 0.12).
Next expected readout: December 2026 · NCT06399835 (registry estimate)
Reported efficacy
Change from baseline in HbA1c (at 24 weeks): Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35% (met)
Result source: NCT04634500
Ertugliflozin · Steglatro
Marketed by Merck & Co. and partners
NCT01986881 · Phase 3 · completed
This trial was randomized, double-blind, and placebo-controlled with over 8,000 participants, giving it strong statistical power, and its primary endpoint was a hard clinical composite (cardiovascular death, non-fatal MI, or non-fatal stroke) rather than a lab surrogate. The trial was designed as a cardiovascular-safety non-inferiority study, and the pre-specified margin was met, with the ertugliflozin-placebo hazard ratio's upper confidence bound (1.114) falling below the 1.3 non-inferiority threshold, demonstrating that ertugliflozin does not increase cardiovascular risk versus placebo in this population.
Next expected readout: January 2028 · NCT07621380 (registry estimate)
Reported efficacy
Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years); Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study) (Baseline and Week 18): Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years (met)
Result source: NCT01986881
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Enavogliflozin | Ertugliflozin |
|---|---|---|
| HbA1c, change | -0.8% vs -0.8%avs dapagliflozinNCT04634500 | -1.0% vs 0.2%−1.2 vs placeboNCT0195867165 other results
|
| Body weight, change (kg) | —Not posted · NCT05376969 | -3.8 vs -1.3−2.5 vs placeboNCT0198688143 other results
|
| HbA1c below 7% | —Not posted · NCT05376969 | 20% vs 16.5%+3.5 vs placeboNCT0198688143 other results
|
| Fasting plasma glucose, change | —Not posted · NCT05376969 | -0.6 vs -0.3−0.4 vs placeboNCT0198688163 other results
|
| 3-point MACE (% with event) | —Not posted · NCT05376969 | —Not posted · NCT03717194 |
HbA1c, change
- Enavogliflozin
- -0.8% vs -0.8%avs dapagliflozinNCT04634500
- Ertugliflozin
- -1.0% vs 0.2%−1.2 vs placeboNCT01958671
65 other results
- -0.9% vs -0.0% NCT02033889
- -0.9% vs -0.1% NCT02036515
- -0.4% vs -0.3% NCT01986855
- -0.9% vs -0.2% NCT02630706
- -0.8% vs -0.2% NCT01986881
- -0.8% vs -0.2% NCT01986881
- -0.8% vs -0.6% NCT01986881
- -1.0% vs -0.2% NCT01986881
- -0.8% vs 0.2% NCT01958671
- -0.7% vs -0.0% NCT02033889
- -0.8% vs -0.1% NCT02036515
- -0.3% vs -0.3% NCT01986855
- -1% vs -0.2% NCT02630706
- -0.9% vs -0.6% NCT01986881
- -0.9% vs -0.2% NCT01986881
- -1.7% vs -0.4% NCT02226003
- -1.6% vs -0.4% NCT02226003
- -0.6% vs 0.1% NCT04029480
- -1.1% vs -1.1% NCT02099110
- -0.6% vs -0.7% NCT01999218
- -1.0% vs -1.1% NCT02099110
- -0.6% vs -0.7% NCT01999218
- -1.5% vs -1.1% NCT02099110
- -1.5% vs -1.1% NCT02099110
- -0.7% vs -0.2% NCT01986881
- -0.7% vs -0.2% NCT01986881
- -0.5% vs -0.1% NCT01986881
- -0.4% vs -0.0% NCT01986881
- -0.2% vs 0.1% NCT01986881
- -0.7% vs -0.2% NCT01986881
- -0.7% vs -0.2% NCT01986881
- -0.5% vs -0.1% NCT01986881
- -0.4% vs -0.0% NCT01986881
- -0.2% vs 0.1% NCT01986881
- -0.3% vs -0.1% NCT01986881
- -0.7% vs -0.7% NCT02033889
- -0.3% vs -0.1% NCT01986881
- -0.4% vs -0.3% NCT01986855
- -1.0% vs -0.7% NCT02033889
- -0.8% vs 0.0% NCT02036515
- -0.9% vs -0.6% NCT02033889
- -0.5% vs 0.3% NCT04029480
- -0.3% vs -0.3% NCT01986855
- -0.8% vs 0.0% NCT02036515
- -0.6% vs -0.6% NCT02033889
- -0.4% vs 0.3% NCT04029480
- -0.2% vs 0.8% NCT04029480
- -0.1% vs 0.2% NCT01986881
- -0.3% vs 0.2% NCT01986881
- -0.8% vs -0.1% NCT01059825
- -0.8% vs -0.1% NCT01059825
- -0.7% vs -0.1% NCT01059825
- -0.6% vs -0.1% NCT01059825
- -0.8% vs -0.1% NCT01059825
- -0.5% vs -0.0% NCT01059825
- -0.3% vs 0% NCT01059825
- -0.8% vs -0.1% NCT01059825
- -0.4% vs -0.0% NCT01059825
- -0.2% vs 0% NCT01059825
- -0.7% vs -0.1% NCT01059825
- -0.5% vs -0.0% NCT01059825
- -0.2% vs 0% NCT01059825
- -0.6% vs -0.1% NCT01059825
- -0.4% vs -0.0% NCT01059825
- -0.1% vs 0% NCT01059825
Body weight, change (kg)
- Enavogliflozin
- —Not posted · NCT05376969
- Ertugliflozin
- -3.8 vs -1.3−2.5 vs placeboNCT01986881
43 other results
- -3.4 vs -1.0 NCT01986881
- -3.2 vs -0.7 NCT01986881
- -2.8 vs -0.4 NCT01986881
- -2.3 vs -0.4 NCT01986881
- -3.4 vs -1.3 NCT01986881
- -3.0 vs -1.0 NCT01986881
- -2.8 vs -0.7 NCT01986881
- -2.5 vs -0.4 NCT01986881
- -2.0 vs -0.4 NCT01986881
- -4.6 vs -1.2 NCT01986881
- -3.6 vs -0.2 NCT02033889
- -3.4 vs 0.1 NCT02033889
- -2.8 vs -0.9 NCT02036515
- -2.9 vs -1.3 NCT02033889
- -2.1 vs -0.3 NCT01986881
- -3.7 vs -1.2 NCT01986881
- -3.6 vs -1.4 NCT01958671
- -3.0 vs -1.3 NCT02036515
- -1.4 vs 0.5 NCT01986855
- -3.2 vs -1.2 NCT02630706
- -3.8 vs -0.2 NCT02033889
- -3.2 vs 0.1 NCT02033889
- -1.9 vs -0.3 NCT01986881
- -1.2 vs -0.7 NCT01986881
- -2.4 vs -0.5 NCT01986881
- -3.5 vs -0.9 NCT02036515
- -3.2 vs -1.4 NCT01958671
- -3.0 vs -1.3 NCT02033889
- -3.4 vs -1.3 NCT02036515
- -1.3 vs 0.5 NCT01986855
- -3.0 vs -1.2 NCT02630706
- -1.8 vs -0.7 NCT01986881
- -2.0 vs -0.5 NCT01986881
- -3.0 vs -0.9 NCT02226003
- -2.9 vs -0.9 NCT02226003
- -7.4 vs -1.0 NCT01986881
- -4.2 vs -1.0 NCT01986881
- -3.4 vs 0.9 NCT01999218
- -3.7 vs -0.7 NCT02099110
- -3.0 vs 0.9 NCT01999218
- -2.7 vs -0.7 NCT02099110
- -2.9 vs -0.7 NCT02099110
- -2.5 vs -0.7 NCT02099110
HbA1c below 7%
- Enavogliflozin
- —Not posted · NCT05376969
- Ertugliflozin
- 20% vs 16.5%+3.5 vs placeboNCT01986881
43 other results
- 22.7% vs 18.2% NCT01986881
- 22.7% vs 16.9% NCT01986881
- 23.8% vs 16.6% NCT01986881
- 29% vs 17.4% NCT01986881
- 28.2% vs 15.5% NCT01986881
- 21.1% vs 10.7% NCT01986881
- 18.6% vs 16.5% NCT01986881
- 24.9% vs 18.2% NCT01986881
- 23.1% vs 16.9% NCT01986881
- 23.9% vs 16.6% NCT01986881
- 28.3% vs 17.4% NCT01986881
- 28.4% vs 15.5% NCT01986881
- 33.7% vs 19.1% NCT02033889
- 36.6% vs 30.6% NCT02033889
- 32.7% vs 13.7% NCT02036515
- 35.8% vs 13.1% NCT01958671
- 40% vs 15.8% NCT02033889
- 39.9% vs 17% NCT02036515
- 40.8% vs 16.2% NCT02630706
- 24.6% vs 19.1% NCT02033889
- 34.8% vs 30.6% NCT02033889
- 33.3% vs 13.7% NCT02036515
- 35.3% vs 15.8% NCT02033889
- 20.7% vs 10.7% NCT01986881
- 11.3% vs 12.1% NCT01986855
- 27.8% vs 25% NCT01986881
- 32.7% vs 12.8% NCT01986881
- 28.2% vs 13.1% NCT01958671
- 32.1% vs 17% NCT02036515
- 16.2% vs 12.1% NCT01986855
- 38.2% vs 16.2% NCT02630706
- 32.7% vs 25% NCT01986881
- 37% vs 12.8% NCT01986881
- 31.3% vs 8.3% NCT02226003
- 35.7% vs 8.3% NCT02226003
- 31.9% vs 32.8% NCT02099110
- 26.4% vs 32.8% NCT02099110
- 49.2% vs 32.8% NCT02099110
- 52.3% vs 32.8% NCT02099110
- 42.9% vs 15.6% NCT01059825
- 36.2% vs 15.6% NCT01059825
- 38.6% vs 15.6% NCT01059825
- 44% vs 15.6% NCT01059825
Fasting plasma glucose, change
- Enavogliflozin
- —Not posted · NCT05376969
- Ertugliflozin
- -0.6 vs -0.3−0.4 vs placeboNCT01986881
63 other results
- -0.9 vs 0.2 NCT01986881
- -1.3 vs -0.2 NCT01986881
- -1.4 vs -0.2 NCT01986881
- -1.6 vs -0.5 NCT01986881
- -1.9 vs -0.9 NCT01986881
- -1.6 vs -0.6 NCT02033889
- -1.5 vs 0.2 NCT02036515
- -1.8 vs -0.4 NCT01986881
- -0.8 vs -0.3 NCT01986881
- -0.8 vs 0.2 NCT01986881
- -1.1 vs -0.2 NCT01986881
- -1.2 vs -0.2 NCT01986881
- -1.6 vs -0.5 NCT01986881
- -1.8 vs -0.9 NCT01986881
- -1.9 vs -0.7 NCT02033889
- -2.4 vs 0.0 NCT01958671
- -2.2 vs -0.1 NCT02033889
- -1.8 vs -0.1 NCT02036515
- -1.1 vs -0.3 NCT01986855
- -1.9 vs -0.4 NCT02630706
- -1.0 vs -0.6 NCT02033889
- -1.2 vs -0.7 NCT02033889
- -1.5 vs -0.4 NCT01986881
- -1.5 vs -0.8 NCT01986881
- -2.0 vs -0.3 NCT01986881
- -1.4 vs 0.2 NCT02036515
- -1.9 vs 0.0 NCT01958671
- -1.5 vs -0.1 NCT02033889
- -1.5 vs -0.1 NCT02036515
- -0.7 vs -0.3 NCT01986855
- -2.1 vs -0.4 NCT02630706
- -1.6 vs -0.8 NCT01986881
- -2.0 vs -0.3 NCT01986881
- -0.7 vs 1.2 NCT04029480
- -1.1 vs 0.5 NCT04029480
- -4.7 vs 0.8 NCT01986881
- -0.1 vs 0.8 NCT01986881
- -2.0 vs -1.4 NCT02099110
- -2.0 vs -1.4 NCT02099110
- -2.7 vs -1.4 NCT02099110
- -2.4 vs -1.4 NCT02099110
- -1.3 vs 0.1 NCT01059825
- -1.4 vs 0.2 NCT01059825
- -1.7 vs 0.2 NCT01096667
- -1.3 vs 0.3 NCT01059825
- -1.3 vs -0.3 NCT01096667
- -0.9 vs 0.3 NCT01059825
- -1.6 vs 0.1 NCT01059825
- -1.7 vs 0.2 NCT01059825
- -1.7 vs 0.2 NCT01096667
- -1.5 vs 0.3 NCT01059825
- -1.8 vs -0.3 NCT01096667
- -0.9 vs 0.3 NCT01059825
- -1.8 vs 0.1 NCT01059825
- -1.8 vs 0.2 NCT01059825
- -1.6 vs 0.3 NCT01059825
- -1.5 vs 0.3 NCT01059825
- -1.0 vs 0.1 NCT01059825
- -1.0 vs 0.2 NCT01059825
- -0.8 vs 0.2 NCT01096667
- -0.9 vs 0.3 NCT01059825
- -0.6 vs -0.3 NCT01096667
- -0.8 vs 0.3 NCT01059825
3-point MACE (% with event)
- Enavogliflozin
- —Not posted · NCT05376969
- Ertugliflozin
- —Not posted · NCT03717194
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Enavogliflozin: 0 of 4 rows · Ertugliflozin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Enavogliflozin | Ertugliflozin |
|---|---|---|
| Dropout rate | — | —15 mga NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results—15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 12.6%15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —15 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 12%5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 15.8%15 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 12.2%5 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 12.2%15 mg NCT02033889 · Phase 3 9.7%5 mg NCT02033889 · Phase 3 22.9%15 mg NCT01999218 · Phase 3 24.3%5 mg NCT01999218 · Phase 3 12.5%15 mg NCT02099110 · Phase 3 9.6%5 mg NCT02099110 · Phase 3 11%15 mg + 100 mg NCT02099110 · Phase 3 · combination 9.1%5 mg + 100 mg NCT02099110 · Phase 3 · combination 7.7%15 mg NCT02036515 · Phase 3 —15 mg NCT02036515 · Phase 3 · combination 3.2%5 mg NCT02036515 · Phase 3 —5 mg NCT02036515 · Phase 3 · combination 1%15 mg + 100 mg NCT02226003 · Phase 3 · combination 2%5 mg + 100 mg NCT02226003 · Phase 3 · combination 9%15 mg NCT01986855 · Phase 3 8.2%5 mg NCT01986855 · Phase 3 —15 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 5.3%15 mg NCT02630706 · Phase 3 · registry result, not featured evidence 4.1%5 mg NCT02630706 · Phase 3 · registry result, not featured evidence 0% NCT03416270 · Phase 2 · registry result, not featured evidence 5.3%5 mg NCT01096667 · Phase 2 · registry result, not featured evidence 7.7%25 mg NCT01096667 · Phase 2 · registry result, not featured evidence 5.1%1 mg NCT01096667 · Phase 2 · registry result, not featured evidence —5 mg NCT01059825 · Phase 2 · registry result, not featured evidence —25 mg NCT01059825 · Phase 2 · registry result, not featured evidence —10 mg NCT01059825 · Phase 2 · registry result, not featured evidence —1 mg NCT01059825 · Phase 2 · registry result, not featured evidence 39.3% NCT04167761 · Phase 1 · registry result, not featured evidence —15 mg Oral + 100 ug Oral NCT02411929 · Phase 1 · registry result, not featured evidence · combination —15 mg Oral + 100 ug IV NCT02411929 · Phase 1 · registry result, not featured evidence · combination 0%15 mg NCT02115347 · Phase 1 · registry result, not featured evidence 0%15 mg NCT02115347 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —4 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence —2 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence —2 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence —1 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | — | —15 mga NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results—15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —15 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0.7%15 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.6%5 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.5%15 mg NCT02033889 · Phase 3 0.5%5 mg NCT02033889 · Phase 3 1.6%15 mg NCT01999218 · Phase 3 2%5 mg NCT01999218 · Phase 3 2%15 mg NCT02099110 · Phase 3 1.2%5 mg NCT02099110 · Phase 3 0.8%15 mg + 100 mg NCT02099110 · Phase 3 · combination 1.2%5 mg + 100 mg NCT02099110 · Phase 3 · combination 0.6%15 mg NCT02036515 · Phase 3 —15 mg NCT02036515 · Phase 3 · combination 0.6%5 mg NCT02036515 · Phase 3 —5 mg NCT02036515 · Phase 3 · combination —15 mg + 100 mg NCT02226003 · Phase 3 · combination —5 mg + 100 mg NCT02226003 · Phase 3 · combination 0%15 mg NCT01986855 · Phase 3 0.6%5 mg NCT01986855 · Phase 3 —15 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 0.6%15 mg NCT02630706 · Phase 3 · registry result, not featured evidence 1.2%5 mg NCT02630706 · Phase 3 · registry result, not featured evidence — NCT03416270 · Phase 2 · registry result, not featured evidence —5 mg NCT01096667 · Phase 2 · registry result, not featured evidence —25 mg NCT01096667 · Phase 2 · registry result, not featured evidence —1 mg NCT01096667 · Phase 2 · registry result, not featured evidence —5 mg NCT01059825 · Phase 2 · registry result, not featured evidence —25 mg NCT01059825 · Phase 2 · registry result, not featured evidence —10 mg NCT01059825 · Phase 2 · registry result, not featured evidence —1 mg NCT01059825 · Phase 2 · registry result, not featured evidence — NCT04167761 · Phase 1 · registry result, not featured evidence —15 mg Oral + 100 ug Oral NCT02411929 · Phase 1 · registry result, not featured evidence · combination —15 mg Oral + 100 ug IV NCT02411929 · Phase 1 · registry result, not featured evidence · combination —15 mg NCT02115347 · Phase 1 · registry result, not featured evidence —15 mg NCT02115347 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —4 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence —2 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence —2 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence —1 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence |
| Serious AEs | — | 7.3%15 mga NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results7.1%15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 34.1%15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.9%15 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9.5%5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 7%5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 34.9%5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.3%5 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 3.9%15 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.1%5 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.8%15 mg NCT02033889 · Phase 3 9.7%5 mg NCT02033889 · Phase 3 7.4%15 mg NCT01999218 · Phase 3 9.2%5 mg NCT01999218 · Phase 3 2%15 mg NCT02099110 · Phase 3 4.8%5 mg NCT02099110 · Phase 3 4.9%15 mg + 100 mg NCT02099110 · Phase 3 · combination 3.7%5 mg + 100 mg NCT02099110 · Phase 3 · combination —15 mg NCT02036515 · Phase 3 2%15 mg NCT02036515 · Phase 3 · combination —5 mg NCT02036515 · Phase 3 8.3%5 mg NCT02036515 · Phase 3 · combination 3.1%15 mg + 100 mg NCT02226003 · Phase 3 · combination 2%5 mg + 100 mg NCT02226003 · Phase 3 · combination 19.4%15 mg NCT01986855 · Phase 3 16.5%5 mg NCT01986855 · Phase 3 3.8%15 mg NCT04029480 · Phase 3 · registry result, not featured evidence 3.2%5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 0%5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 4.5%5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 5.9%15 mg NCT02630706 · Phase 3 · registry result, not featured evidence 5.3%5 mg NCT02630706 · Phase 3 · registry result, not featured evidence 17.6% NCT03416270 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01096667 · Phase 2 · registry result, not featured evidence 0%25 mg NCT01096667 · Phase 2 · registry result, not featured evidence 0%1 mg NCT01096667 · Phase 2 · registry result, not featured evidence 3.6%5 mg NCT01059825 · Phase 2 · registry result, not featured evidence 1.8%25 mg NCT01059825 · Phase 2 · registry result, not featured evidence 0%10 mg NCT01059825 · Phase 2 · registry result, not featured evidence 0%1 mg NCT01059825 · Phase 2 · registry result, not featured evidence 0% NCT04167761 · Phase 1 · registry result, not featured evidence 0%15 mg Oral + 100 ug Oral NCT02411929 · Phase 1 · registry result, not featured evidence · combination 0%15 mg Oral + 100 ug IV NCT02411929 · Phase 1 · registry result, not featured evidence · combination 0%15 mg NCT02115347 · Phase 1 · registry result, not featured evidence 0%15 mg NCT02115347 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%4 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence 0%2 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence 0%2 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence 0%1 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | — | 15 mga hypoglycaemia 30.3% (placebo 31.4%) nasopharyngitis 3.5% (placebo 3.2%) upper respiratory tract infection 2.7% (placebo 2.6%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 44 more results15 mg hypoglycaemia 16.8% (placebo 31.4%) nasopharyngitis 4.4% (placebo 3.2%) dizziness 3.5% (placebo 1.2%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 15 mg hypoglycaemia 31.1% (placebo 31.4%) urinary tract infection 9.5% (placebo 2%) nasopharyngitis 7.4% (placebo 3.2%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 15 mg hypoglycaemia 5.6% (placebo 31.4%) urinary tract infection 1.9% (placebo 2%) back pain 0% (placebo 0.6%) NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 29% (placebo 31.4%) dizziness 2.3% (placebo 1.2%) upper respiratory tract infection 2.3% (placebo 2.6%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 13% (placebo 31.4%) hypertension 4% (placebo 0.6%) hyperglycaemia 3% (placebo 1.7%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 32.2% (placebo 31.4%) urinary tract infection 9.3% (placebo 2%) upper respiratory tract infection 7.2% (placebo 2.6%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 5.5% (placebo 31.4%) back pain 3.6% (placebo 0.6%) hypertension 3.6% (placebo 0.6%) NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 15 mg nasopharyngitis 7.2% (placebo 3.9%) upper respiratory tract infection 6.6% (placebo 5.9%) urinary tract infection 6.6% (placebo 12.4%) NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg urinary tract infection 8.3% (placebo 12.4%) vulvovaginal mycotic infection 7.7% (placebo 1.3%) constipation 7.1% (placebo 2.6%) NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 15 mg upper respiratory tract infection 10.2% (placebo 15.8%) back pain 9.8% (placebo 4.8%) hypoglycaemia 8.8% (placebo 20.6%) NCT02033889 · Phase 3 5 mg upper respiratory tract infection 11.1% (placebo 15.8%) headache 6.8% (placebo 4.8%) hypoglycaemia 6.8% (placebo 20.6%) NCT02033889 · Phase 3 5 mg upper respiratory tract infection 6.1% urinary tract infection 6.1% headache 5.6% NCT01999218 · Phase 3 15 mg + 100 mg hypoglycaemia 8.2% nasopharyngitis 4.9% urinary tract infection 3.3% NCT02099110 · Phase 3 · combination 5 mg + 100 mg urinary tract infection 5.8% nasopharyngitis 4.9% hypoglycaemia 3.7% NCT02099110 · Phase 3 · combination 15 mg nasopharyngitis 3.9% (placebo 3.3%) hypoglycaemia 3.3% (placebo 7.2%) urinary tract infection 3.3% (placebo 5.2%) NCT02036515 · Phase 3 · combination 5 mg back pain 5.1% (placebo 3.9%) nasopharyngitis 5.1% (placebo 3.3%) hypoglycaemia 4.5% (placebo 7.2%) NCT02036515 · Phase 3 · combination 15 mg + 100 mg urinary tract infection 2.1% (placebo 1%) hyperglycaemia 1% (placebo 6.2%) blood glucose increased 0% (placebo 7.2%) NCT02226003 · Phase 3 · combination 5 mg + 100 mg urinary tract infection 5.1% (placebo 1%) blood glucose increased 3.1% (placebo 7.2%) hyperglycaemia 0% (placebo 6.2%) NCT02226003 · Phase 3 · combination 15 mg hypoglycaemia 20.6% (placebo 29.2%) urinary tract infection 7.7% (placebo 9.7%) upper respiratory tract infection 7.1% (placebo 4.5%) NCT01986855 · Phase 3 5 mg hypoglycaemia 31% (placebo 29.2%) diarrhoea 6.3% (placebo 5.8%) cough 5.7% (placebo 1.3%) NCT01986855 · Phase 3 15 mg hypoglycaemia 19.2% (placebo 12.7%) nausea 15.4% (placebo 7.3%) vomiting 15.4% (placebo 5.5%) NCT04029480 · Phase 3 · registry result, not featured evidence 5 mg upper respiratory tract infection 14.3% (placebo 10.9%) hypoglycaemia 11.1% (placebo 12.7%) covid-19 7.9% (placebo 7.3%) NCT04029480 · Phase 3 · registry result, not featured evidence 5 mg hypoglycaemia 11.5% (placebo 12.7%) nausea 7.7% (placebo 7.3%) vomiting 7.7% (placebo 5.5%) NCT04029480 · Phase 3 · registry result, not featured evidence 5 mg nausea 13.6% (placebo 7.3%) abdominal pain 9.1% (placebo 5.5%) diarrhoea 9.1% (placebo 7.3%) NCT04029480 · Phase 3 · registry result, not featured evidence 15 mg hyperuricaemia 5.3% (placebo 12%) hypoglycaemia 5.3% (placebo 1.2%) nasopharyngitis 5.3% (placebo 6.6%) NCT02630706 · Phase 3 · registry result, not featured evidence 5 mg nasopharyngitis 5.3% (placebo 6.6%) hypoglycaemia 3.5% (placebo 1.2%) hyperuricaemia 2.9% (placebo 12%) NCT02630706 · Phase 3 · registry result, not featured evidence 5 mg genital infection fungal 7.9% (placebo 0%) athralgia 5.3% (placebo 0%) nasopharyngitis 5.3% (placebo 0%) NCT01096667 · Phase 2 · registry result, not featured evidence 25 mg fatigue 5.1% (placebo 0%) polyuria 5.1% (placebo 0%) dizziness 2.6% (placebo 5.3%) NCT01096667 · Phase 2 · registry result, not featured evidence 1 mg musculoskeletal pain 5.1% (placebo 0%) upper respiratory tract infection 2.6% (placebo 5.3%) urinary tract infection 2.6% (placebo 2.6%) NCT01096667 · Phase 2 · registry result, not featured evidence 5 mg arthralgia 10.9% (placebo 1.9%) headache 7.3% (placebo 3.7%) hypoglycaemia 5.5% (placebo 0%) NCT01059825 · Phase 2 · registry result, not featured evidence 25 mg genital infection fungal 7.3% (placebo 1.9%) diarrhoea 5.5% (placebo 1.9%) upper respiratory tract infection 5.5% (placebo 3.7%) NCT01059825 · Phase 2 · registry result, not featured evidence 10 mg urinary tract infection 9.1% (placebo 7.4%) genital infection fungal 5.5% (placebo 1.9%) upper respiratory tract infection 5.5% (placebo 3.7%) NCT01059825 · Phase 2 · registry result, not featured evidence 1 mg arthralgia 3.7% (placebo 1.9%) diarrhoea 3.7% (placebo 1.9%) upper respiratory tract infection 3.7% (placebo 3.7%) NCT01059825 · Phase 2 · registry result, not featured evidence 15 mg Oral + 100 ug Oral nasal congestion 12.5% back pain 0% headache 0% NCT02411929 · Phase 1 · registry result, not featured evidence · combination 15 mg Oral + 100 ug IV headache 25% back pain 12.5% nasal congestion 0% NCT02411929 · Phase 1 · registry result, not featured evidence · combination 15 mg decreased appetite 12.5% headache 12.5% tachycardia 12.5% NCT02115347 · Phase 1 · registry result, not featured evidence 15 mg arthralgia 12.5% back pain 12.5% dizziness 12.5% NCT02115347 · Phase 1 · registry result, not featured evidence 4 mg Once Daily diarrhoea 11.5% headache 7.7% abdominal pain 3.8% NCT01054300 · Phase 1 · registry result, not featured evidence 2 mg Once Daily headache 11.5% constipation 3.8% dizziness 3.8% NCT01054300 · Phase 1 · registry result, not featured evidence 2 mg Twice Daily abdominal pain 3.8% diarrhoea 3.8% dry mouth 3.8% NCT01054300 · Phase 1 · registry result, not featured evidence 1 mg Twice Daily headache 12% back pain 4% dyspepsia 4% NCT01054300 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 44 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ertugliflozin
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 43 more results
show 23 more results
show 63 more results
show 36 more results
show 32 more results
show 43 more results
show 13 more results
show 13 more results
+ 30 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Enavogliflozin's landscape · Ertugliflozin's landscape